Vaccination with the Covid dual-dose vaccine does not produce enough neutralizing antibodies against the Omicron variant, according to a British study showing that an increase in cases among those infected or fully vaccinated is possible.
Researchers at the University of Oxford today published large-scale results of a combination of peer-reviewed research vaccines that analyzed blood samples from people who received doses of AstraZeneca-Oxford and Pfizer-BioNTech vaccines.
The results come a day after British Prime Minister Boris Johnson warned that two doses of the vaccine would not be enough to treat Omicron, following findings from a UK Health Service study that showed booster doses greatly restored protection against variation.
The Oxford University study points out that there is no evidence that low levels of anti-Omicron antibodies will lead to a higher risk of serious illness, hospitalization and death in those who have received two doses of approved vaccines.
“These data are important, but they are only part of the picture. “They only study neutralizing antibodies after the second dose, but they do not provide information on cellular immunity and this will also be investigated,” said Matthew Snape, a professor at Oxford University and one of the study’s authors.
Follow Skai.gr on Google News
and be the first to know all the news
.
